In a SELECT trial involving 17,604 patients with a BMI of 27 or higher and preexisting cardiovascular disease, but without diabetes, weekly subcutaneous semaglutide reduced the risk of composite death by cardiovascular events by 20% [43]
Nakawa and our team provide expert, physician-guided weight loss solutions built for lasting success
The most evidence-backed weight loss peptide options in 2026 are GLP-1 medications like semaglutide and tirzepatide for appetite-driven weight loss, and Tesamorelin for targeted visceral fat reduction in a specific FDA-approved use case
Particular attention is needed for insulin and sulfonylureas (hypoglycemia risk), oral contraceptives (reduced absorption), thyroid medications (altered absorption timing), and blood thinners (variable absorption)
Want a doctor who actually cares
But what if youre not ready for injections